Table 1.
Patients and tumor characteristics.
| Characteristics | |
|---|---|
| Gender | |
| Male | 68 |
| Female | 74 |
| Tumor location | |
| Colon | 6 |
| Rectum | 136 |
| Lymph node status | |
| N0 | 50 |
| N1 | 64 |
| N2, N3 | 28 |
| Diagnosis of carcinomatosis | |
| Synchronous carcinomatosis | 59 |
| Metachronous carcinomatosis | 83 |
| Systemic chemotherapy prior to cytoreduction | |
| None | 32 |
| FOLFOX (+bevacizumab; BV) | 60 (24) |
| FOLFIRI (+BV or +cetuximab) | 17 (2, 5) |
| Xeloda (+oxaliplatin or +BV) | 17 (14, 5) |
| S1 (+paclitaxel) | 10 (5) |
| Others (IRIS#, TJ$, SOX&, and HIPEC¥) | 6 |
#IRIS: Irinotecan +S1, $TJ: taxol + CBDCA.
&SOX: S1+ Oxaliplatin.
¥HIPEC: hyperthermic intraperitoneal chemotherapy.